An optimized microRNA backbone for effective single-copy RNAi C Fellmann, T Hoffmann, V Sridhar, B Hopfgartner, M Muhar, M Roth, ... Cell reports 5 (6), 1704-1713, 2013 | 737 | 2013 |
Cornerstones of CRISPR-Cas in drug discovery and therapy C Fellmann, BG Gowen, PC Lin, JA Doudna, JE Corn Nature Reviews Drug Discovery 16 (2), 89-100, 2017 | 479 | 2017 |
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors P Lito, A Saborowski, J Yue, M Solomon, E Joseph, S Gadal, ... Cancer Cell 25 (5), 697-710, 2014 | 316 | 2014 |
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi J Zuber, K McJunkin, C Fellmann, LE Dow, MJ Taylor, GJ Hannon, ... Nature biotechnology 29 (1), 79-83, 2011 | 312 | 2011 |
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance J Zuber, AR Rappaport, W Luo, E Wang, C Chen, AV Vaseva, J Shi, ... Genes & development 25 (15), 1628-1640, 2011 | 297 | 2011 |
Functional identification of optimized RNAi triggers using a massively parallel sensor assay C Fellmann, J Zuber, K McJunkin, K Chang, CD Malone, RA Dickins, Q Xu, ... Molecular cell 41 (6), 733-746, 2011 | 270 | 2011 |
HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase A Sendoel, I Kohler, C Fellmann, SW Lowe, MO Hengartner Nature 465 (7298), 577-583, 2010 | 255 | 2010 |
Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors TP Huang, KT Zhao, SM Miller, NM Gaudelli, BL Oakes, C Fellmann, ... Nature biotechnology 37 (6), 626-631, 2019 | 250 | 2019 |
Stable RNA interference rules for silencing C Fellmann, SW Lowe Nature cell biology 16 (1), 10-18, 2014 | 222 | 2014 |
Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch BL Oakes, DC Nadler, A Flamholz, C Fellmann, BT Staahl, JA Doudna, ... Nature biotechnology 34 (6), 646-651, 2016 | 211 | 2016 |
Systematic discovery of natural CRISPR-Cas12a inhibitors KE Watters, C Fellmann, HB Bai, SM Ren, JA Doudna Science 362 (6411), 236-239, 2018 | 203 | 2018 |
A pipeline for the generation of shRNA transgenic mice LE Dow, PK Premsrirut, J Zuber, C Fellmann, K McJunkin, C Miething, ... Nature protocols 7 (2), 374-393, 2012 | 197 | 2012 |
Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAs K Kundert, JE Lucas, KE Watters, C Fellmann, AH Ng, BM Heineike, ... Nature Communications 10 (1), 2127, 2019 | 170 | 2019 |
Prediction of potent shRNAs with a sequential classification algorithm R Pelossof, L Fairchild, CH Huang, C Widmer, VT Sreedharan, N Sinha, ... Nature Biotechnology 35 (4), 350-353, 2017 | 151 | 2017 |
Disruption of the β1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner A Mancini, A Xavier-Magalhães, WS Woods, KT Nguyen, AM Amen, ... Cancer Cell 34 (3), 513-528. e8, 2018 | 125 | 2018 |
Development of siRNA payloads to target KRAS-mutant cancer TL Yuan, C Fellmann, CS Lee, CD Ritchie, V Thapar, LC Lee, DJ Hsu, ... Cancer discovery 4 (10), 1182-1197, 2014 | 123 | 2014 |
Differential Effector Engagement by Oncogenic KRAS TL Yuan, A Amzallag, R Bagni, M Yi, S Afghani, W Burgan, N Fer, ... Cell Reports 22 (7), 1889-1902, 2018 | 120 | 2018 |
A Computational Algorithm to Predict shRNA Potency SRV Knott, AR Maceli, N Erard, K Chang, K Marran, X Zhou, A Gordon, ... Molecular cell 56 (6), 796-807, 2014 | 117 | 2014 |
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival CS Lee, LC Lee, TL Yuan, S Chakka, C Fellmann, SW Lowe, NJ Caplen, ... Proceedings of the National Academy of Sciences 116 (10), 4508-4517, 2019 | 112 | 2019 |
CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification BL Oakes, C Fellmann, H Rishi, KL Taylor, SM Ren, DC Nadler, R Yokoo, ... Cell 176 (1-2), 254-267. e16, 2019 | 107 | 2019 |